First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
Published version of a preprint
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: This phase I study assessed the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetics, pharmacodynamics, and clinical activity of the first-in-class dual MEK/RAF inhibitor, RO5126766. Experimental Design: Initial dose-escalation was conducted using once daily dosing over 28 consecutive days in 4-week cycles. Further escalation was completed using 2 intermittent dosing schedules [7 days on treatment followed by 7 days off (7on/7off); 4 days on treatment followed by 3 days off (4on/3off)]. Results: Fifty-two patients received RO5126766 at doses of 0.1 to 2.7 mg once daily, 2.7 to 4.0 mg (4 on/3 off), or 2.7 to 5.0 mg (7 on/7 off). The most common DLTs were elevated creatine phosphokinase (CPK) and blurred vision. The MTD for each dosing schedule was 2.25 mg once daily, 4.0 mg (4 on/3 off), and 2.7 mg (7 on/7 off). The dose/schedule recommended for phase II (RP2D) investigation was 2.7 mg (4 on/3 off). Frequent adverse events included rash-related disorders (94.2%), elevated CPK (55.8%), and diarrhea (51.9%). Cmax occurred 1 to 2 hours after dosing and mean terminal half-life was approximately 60 hours. Pharmacodynamic changes included reduced ERK phosphorylation, an increase in apoptosis in tumor tissue, and a reduction in fluorodeoxyglucose (FDG) uptake after 15 days of dosing. Three partial responses were seen: two in BRAF-mutant melanoma tumors and one in an NRAS-mutant melanoma. Conclusion: This first-in-human study shows that oral RO5126766 has manageable toxicity, a favorable pharmacokinetic/pharmacodynamic profile, and encouraging preliminary antitumor activity in this population of heavily pretreated patients, achieving tumor shrinkage in around 40% of patients across all dose levels and all tumor types. Clin Cancer Res; 18(17); 4806–19. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
The MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185
Research works printed but not linked: 38
- Pearson, 2001, Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions, Endocr Rev, 22, 153
- Hoshino, 1999, Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors, Oncogene, 18, 813, 10.1038/sj.onc.1202367 · DOI · Paper page
- Bos, 1989, Ras Oncogenes in Human Cancer: A Review, Cancer Res, 49, 4682
- Cohen, 2003, BRAF mutation in papillary thyroid carcinoma, J Natl Cancer Inst, 95, 625, 10.1093/jnci/95.8.625 · DOI · Paper page
- Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 · DOI · Paper page
- Xu, 2003, High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines, Cancer Res, 63, 4561
- Adjei, 2008, Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers, J Clin Oncol, 26, 2139, 10.1200/JCO.2007.14.4956 · DOI · Paper page
- Davies, 2007, AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models, Mol Cancer Ther, 6, 2209, 10.1158/1535-7163.MCT-07-0231 · DOI · Paper page
- Gilmartin, 2008, GSK1120212 is a novel Mek inhibitor demonstrating sustained inhibition of ERK phosphorylation and selective inhibition of B-Raf and RAS mutant cells in preclinical models, Eur J Cancer Suppl, 6, 178, 10.1016/S1359-6349(08)72501-1 · doi:10.1016/s1359-6349(08)72501-1
- Lang, AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy, J Clin Oncol
- Lorusso, A Phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer, J Clin Oncol
- Miner, 2008, Selective MEK Inhibitor RDEA119 exhibits efficacy in orthotopic hepatoma models and cytostatic potential in multiple cell based models of cancer, Eur J Cancer Suppl, 6, 181, 10.1016/S1359-6349(08)72511-4 · doi:10.1016/s1359-6349(08)72511-4
- Schwartz, A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors, Eur J Cancer
- Kopetz, PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors, J Clin Oncol
- Kefford, Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors, J Clin Oncol
- Banerji, 2010, The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer, Clin Cancer Res, 16, 1613, 10.1158/1078-0432.CCR-09-2483 · DOI · Paper page
- Flaherty, 2010, Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med, 363, 809, 10.1056/NEJMoa1002011 · DOI · Paper page
- O'Neil, 2011, Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 29, 2350, 10.1200/JCO.2010.33.9432 · DOI · Paper page
- Bekaii-Saab, 2011, Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers, J Clin Oncol, 29, 2357, 10.1200/JCO.2010.33.9473 · DOI · Paper page
- Little, 2011, Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells, Sci Signal, 4, 10.1126/scisignal.2001752 · DOI · Paper page
- Cichowski, 2010, Drug discovery: inhibitors that activate, Nature, 464, 358, 10.1038/464358a · doi:10.1038/464358a
- Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 · DOI · Paper page
- Delord, 2010, First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors, J Clin Oncol, 28, 15s, 10.1200/jco.2010.28.15_suppl.2504 · DOI
- Lee, 2009, The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker, Clin Cancer Res, 15, 7368, 10.1158/1078-0432.CCR-09-1696 · DOI · Paper page
- Rojo, 2006, Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma, J Clin Oncol, 24, 4309, 10.1200/JCO.2005.04.2424 · DOI · Paper page
- Young, 1999, Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group, Eur J Cancer, 35, 1773, 10.1016/S0959-8049(99)00229-4 · DOI · Paper page
- Lorusso, 2010, Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers, Clin Cancer Res, 16, 1924, 10.1158/1078-0432.CCR-09-1883 · DOI · Paper page
- Thompson, 2009, A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor, administered orally to subjects with solid tumors or lymphoma, J Clin Oncol, 27, 10.1200/jco.2009.27.15_suppl.e14584 · doi:10.1200/jco.2009.27.15_suppl.e14584
- Shapiro, 2011, Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors, J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.3005 · DOI · Paper page
- Kurzrock, 2011, Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795), J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.3085 · DOI · Paper page
- Gore, 2011, Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86–9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer, J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.3007 · DOI
- Infante, 2011, Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436), J Clin Oncol, 29, 10.1200/jco.2011.29.18_suppl.cra8503 · DOI
- Rinehart, 2004, Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer, J Clin Oncol, 22, 4456, 10.1200/JCO.2004.01.185 · DOI · Paper page
- Ciuffini, 2008, Delineating v-Src downstream effector pathways in transformed myoblasts, Oncogene, 27, 528, 10.1038/sj.onc.1210665 · DOI
- Kolch, 2000, Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions, Biochem J, 351, 289, 10.1042/bj3510289 · DOI · Paper page
- Garcia, 2009, Regulation of human myoblast differentiation by PEBP4, EMBO Rep, 10, 278, 10.1038/embor.2009.4 · DOI
- Lawlor, 2000, Dual control of muscle cell survival by distinct growth factor-regulated signaling pathways, Mol Cell Biol, 20, 3256, 10.1128/MCB.20.9.3256-3265.2000 · DOI
- Lorusso, 2005, Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies, J Clin Oncol, 23, 5281, 10.1200/JCO.2005.14.415 · DOI · Paper page
Cited by
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Yuan, J., Dong, X., Yap, J., & Hu, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00949-4 · Cited by 493
Therapeutic strategies to target RAS-mutant cancers
Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420
The clinical development of MEK inhibitors
Zhao, Y., & Adjei, A. A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.83 · Cited by 400
Metadata
- Authors
- Martinez-Garcia, M., Banerji, U., Albanell, J., Bahleda, R., Dolly, S., Kraeber-Bodéré, F., Rojo, F., Routier, E., Guarin, E., Xu, Z.-X., Rueger, R., Tessier, J. J. L., Shochat, E., Blotner, S., Naegelen, V. M., & Soria, J.-C.
- Venue
- Clinical Cancer Research
- Published
- 2012-08-30
- Volume
- 18
- Issue
- 17
- Pages
- 4806-4819
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2118549562
- Cited by
- 151
- References
- 3
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-0742
- The paper
- Martinez-Garcia, M., Banerji, U., Albanell, J., Bahleda, R., Dolly, S., Kraeber-Bodéré, F., Rojo, F., Routier, E., Guarin, E., Xu, Z.-X., Rueger, R., Tessier, J. J. L., Shochat, E., Blotner, S., Naegelen, V. M., & Soria, J.-C. (2012). First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-0742
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.